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Role of RhoA and Rho Kinase in Lysophosphatidic
Acid–Induced Endothelial Barrier Dysfunction
Geerten P. van Nieuw Amerongen, Mario A. Vermeer, Victor W.M. van Hinsbergh
Abstract—In the present study, the roles of the small GTPase RhoA and its target Rho kinase in endothelial permeability
were investigated in vitro. We have shown previously that, in addition to a rise in the intracellular Ca21 concentration
([Ca21]i), RhoA is involved in the prolonged thrombin-induced barrier dysfunction. To study the role of RhoA and Rho
kinase more specifically, endothelial cells were stimulated with lysophosphatidic acid (LPA), a commonly used RhoA
activator. LPA induced a 2- to 3-fold increase in the passage of horseradish peroxidase (HRP) across endothelial
monolayers that lasted for several hours, whereas thrombin induced a 5- to 10-fold increase. Comparable to the
thrombin-induced barrier dysfunction, the LPA-induced barrier dysfunction was accompanied by a reorganization of the
F-actin cytoskeleton and the formation of focal attachment sites. LPA induced only a transient increase in myosin
light-chain (MLC) phosphorylation, which returned to basal level within 10 minutes. In endothelial cells, [Ca21]i was
not elevated by LPA. Chelation of Ca21i ions by 1,2-bis(2-aminophenoxy)ethane-N,N,N9,N9-tetraacetic acid did not
prevent the LPA-induced passage of HRP. Apparently, a low degree of MLC kinase activation occurred, because the
MLC kinase inhibitor KT5926 reduced the levels of both basal and LPA-stimulated HRP passage. Inhibition of RhoA
by the C3 transferase from Clostridium botulinum inhibited the LPA-induced cytoskeletal changes and prevented the
LPA-induced HRP passage. Inhibition of Rho kinase by Y-27632 completely prevented the LPA-induced increase in
HRP passage without affecting basal permeability. These data indicate that LPA-induced endothelial hyperpermeability
occurs without a change in [Ca21]i and requires activation of RhoA and Rho kinase. (Arterioscler Thromb Vasc Biol.
2000;20:e127-e133.)
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The endothelium, which forms the inner lining of all bloodvessels, is a highly selective barrier for blood constitu-
ents. Formation of gaps between endothelial cells (ECs), for
instance during inflammation, leads to extravasation of fluid
and macromolecules and may cause life-threatening edema.
This gap formation is based on an actin–nonmuscle myosin
contraction process at the margins of the cell. Analogous to
smooth muscle cell contraction, phosphorylation of the my-
osin light chain (MLC) by the Ca21/calmodulin-dependent
kinase I, the classic MLC kinase, directs the actin-myosin–
based contraction process in ECs and is dependent on calcium
ions and calmodulin.1
In the past few years, it has become clear that MLC
phosphorylation is a highly regulated process in which the
small G proteins play an eminent role. In HeLa cells,
overexpression of the p21-activated kinase,2 an enzyme that
is activated by the small GTPases Cdc42 and Rac, reduces
MLC kinase activity, whereas in ECs, p21-activated kinase
increases MLC phosphorylation.3 The small GTPase RhoA,
in addition to an elevation of the intracellular Ca21 concen-
tration [Ca21]i, is involved in the prolonged endothelial
barrier dysfunction and elevated MLC phosphorylation levels
induced by thrombin.4,5 Soluble factors from serum such as
lysophosphatidic acid (LPA) and sphingosine 1-phosphate
are thought to activate RhoA.6,7 To address the question of
whether activation of RhoA per se induces prolonged endo-
thelial barrier dysfunction, we studied the effects of LPA on
endothelial barrier function and investigated the mechanisms
by which RhoA can induce endothelial permeability.
The phospholipid LPA is known to be formed by and
released from activated platelets and can be generated by the
action of secretory phospholipase A2. Interestingly, Siess et
al8 have recently shown that mild oxidation of LDL also
generates biologically active LPA, thus stimulating platelet
activation and endothelial stress-fiber formation. LPA binds
to the Edg subfamily of high-affinity, G protein–coupled
heptahelical receptors, by which it can activate various
second messengers, including RhoA, via G12/13.9 When RhoA
is activated, GDP is exchanged for GTP. Activation of RhoA
can be inhibited by the Clostridium botulinum C3 transferase
toxin, which specifically ADP-ribosylates RhoA at
Asn41.10,11 In its GTP-bound form, RhoA interacts with
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several downstream targets, such as protein kinase N, Rho
kinase, rhotekin, rhophilin, phosphatidylinositol 4-phosphate
5-kinase, citron, and p140mDia (reviewed in References 12
through 14).
A good candidate for the Rho-induced cytoskeletal
changes and cell contraction is Rho kinase. Rho kinase was
shown to be involved in the formation of focal adhesion
complexes15,16 and to increase MLC phosphorylation by
inhibition of myosin phosphatase activity17,18 and possibly,
by direct MLC phosphorylation.19 Uehata et al20 and Ishizaki
et al21 recently described a synthetic pyridine analogue that
inhibits Rho kinase with high specificity compared with MLC
kinase. This cell-permeant inhibitor, Y-27632, was able to
prevent Rho-mediated stress-fiber formation and smooth
muscle contraction. In the present study, we investigated the
effects of LPA-induced RhoA activation on EC permeability
and used Y-27632 to demonstrate the involvement of Rho
kinase in the LPA-enhanced endothelial permeability.
Methods
Materials
Tissue-culture plasticware and Transwells (diameter 0.65 cm, pore
size 3 mm) were obtained from Costar; cell-culture reagents used
were as previously described.4 Bovine thrombin was from Leo
Pharmaceutical Products. Horseradish peroxidase (HRP), LPA
(stored under N2), and anti-vinculin immunoglobulin were obtained
from Sigma Chemical Co.22 1,2-bis(2-Aminophenoxy)ethane-
N,N,N9,N9-tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA-
AM) and rhodamine-phalloidin were from Molecular Probes.
Pyrogen-free human serum albumin (HSA) was from the Central
Laboratory of the Blood Transfusion Service (Amsterdam, The
Netherlands). C3 transferase toxin was kindly provided by Dr A.
Ridley (Ludwig Institute, London, UK). [32P]orthophosphoric acid,
Tran35S label, and KT5926 were from ICN Pharmaceuticals, Inc.
Tritiated LPA (specific activity, 30 to 60 Ci/mmol) was from NEN
Life Science Products, Inc. Anti-platelet myosin immunoglobulin
(nonmuscle) was from Sanbio; rabbit anti-mouse IgG-FITC was
from Dakopatts. Y-27632 was supplied by Welfide Corporation.
Cell Culture and Evaluation of Barrier Function
Human umbilical vein ECs were isolated and cultured as previously
indicated.23,24 One hour before stimulation with LPA, confluent
endothelial monolayers were deprived of serum and kept in medium
199 with 1% HSA. Unless indicated otherwise, ECs were stimulated
with 13 mmol/L LPA. Based on the dilution of LPA, 20 mmol/L was
expected to be added. Because LPA binds to culture plasticware, the
actual LPA concentration was determined by using tritiated LPA to
monitor its fate during dilution. Instead of 20 mmol/L, the actual
concentration during incubation was 13.161.8 mmol/L (mean6SD,
n56). Values of LPA concentrations are given after correction for
tritiated LPA recovery. Barrier function was evaluated by the
transfer of HRP across human umbilical vein EC monolayers grown
on fibronectin-coated polycarbonate filters of the Transwell system.4
MLC Phosphorylation
MLC phosphorylation was measured by the double-labeling tech-
nique. To that end, human umbilical vein ECs were incubated for 24
hours with 150 mCi/mL of Tran35S-label and for 2 hours with 150
mCi/mL of [32P]orthophosphoric acid in phosphate-free buffer before
stimulation of the cells. Details have been given previously.4
Extraction and Assay of Intracellular cAMP
and [Ca21]i
Intracellular cAMP levels were determined by radioimmunoassay
(Amersham) as described previously.4,23 [Ca21]i levels were deter-
mined by the fura 2 method as indicated previously.23 As a positive
control, cells were permeabilized with 10 mmol/L ionomycin, and
afterward, the Ca21 ions were displaced from fura 2 by incubation
with 1 mmol/L MnCl2.
Immunocytochemistry
The presence of vinculin and F-actin was visualized by indirect
immunofluorescence with mouse anti-vinculin antibody and by
direct staining with rhodamine-phalloidin.
Statistical Analysis
Data are reported as mean6SEM. Comparisons between .2 groups
were made by 1-way ANOVA, followed by a Bonferroni-adjusted x2
test. Differences were considered significant at the P,0.05 level.
Results
LPA Induces a Prolonged Decrease in Endothelial
Barrier Function
LPA induced an increase in endothelial permeability for HRP
(filled circles in Figure I compared with basal HRP passage,
as indicated by open circles). Comparable to the thrombin-
induced increase in HRP passage (filled triangles in Figure
I-A), the LPA-induced increase in permeability lasted for
several hours. Although highly significant, the increase in
HRP passage after stimulation by LPA was considerably
lower compared with the 5- to 10-fold increase in permeabil-
ity that is usually observed after stimulation by thrombin and
was just doubled after 1 hour (43.968.7 versus 21.464.6 ng z
cm-2 z h21 in unstimulated monolayers; mean6SEM of 9
cultures in triplicate, P,0.001). The effect of LPA on barrier
Figure I. Endothelial permeability is increased by LPA in a time-
and concentration-dependent manner and is accompanied by
changes in the F-actin cytoskeleton. A, Time curve of LPA-
induced HRP passage across endothelial monolayers. Endothe-
lial monolayers were stimulated with 13 mmol/L LPA (F) or 1
U/mL thrombin () or were incubated without stimulation (E),
and passage of HRP molecules was measured as described in
Methods. Values are mean6SEM of 6 filter cultures in triplicate.
*P,0.05, cells that were stimulated with LPA vs sham-treated
cells. B, Concentration curve of LPA-induced HRP passage
across endothelial monolayers. HRP passage was determined 1
hour after sham treatment (C) or exposure to the indicated con-
centrations of LPA. Values are mean6SEM of 6 filter cultures in
triplicate. C, LPA induced changes in the F-actin cytoskeleton.
ECs were stimulated with 13 mmol/L LPA, fixed at the time
points indicated, and stained for F-actin with rhodamine-
phalloidin. Similar results were observed in 4 different cultures.
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function was concentration dependent and started in the low
micromolar range (Figure I-B).
The LPA-induced change in endothelial permeability was
accompanied by changes in the F-actin cytoskeleton. In
control ECs, F-actin filaments were organized in a cortical
network (Figure I-C). Two minutes after activation with LPA,
short F-actin filaments were formed. After 10 minutes, the
F-actin content was further increased; thin fibers formed and
small gaps between the cells became visible. The number of
F-actin fibers was maximal at 30 and 60 minutes. After 120
minutes, stress fibers disappeared completely.
LPA Induces a Transient Phosphorylation of
the MLCs
The parallel increase in F-actin filaments and enhanced
endothelial permeability induced by LPA assumes an accom-
panying increase in MLC phosphorylation. LPA induced a
transient increase in MLC phosphorylation, which was max-
imal 2 minutes after LPA addition and returned to basal levels
within 10 minutes after LPA stimulation (Figure II). In
contrast, after a 10-minute stimulation by thrombin, MLC
phosphorylation levels were still elevated (163617% com-
pared with basal levels; mean6SEM of 3 cultures in dupli-
cate), and MLC phosphorylation remained elevated for at
least 30 minutes, as was shown previously (see the inset to
Figure 5 in Reference 4).
Ca21 Ions and cAMP Are Not Involved in
LPA-Induced HRP Passage
A transient elevation of [Ca21]i is involved in the thrombin-
induced barrier dysfunction.25–27 We investigated whether
LPA could also induce a rise in [Ca21]i in human umbilical
vein ECs, as was shown in a variety of cell types,28 although
those authors reported that several cell types lacked this Ca21
response. We found that LPA did not elevate [Ca21]i (Figure
III-A), whereas thrombin induced a transient rise in [Ca21]i in
the same EC monolayers. To further exclude a role for Ca21
ions in the LPA-induced passage of HRP molecules, we
pretreated the ECs with the intracellular Ca21 chelator
BAPTA. Preincubation with 3 mmol/L BAPTA did not affect
the LPA-induced passage of HRP (Figure III-B), whereas
BAPTA completely blocked the Ca21-dependent increase in
permeability abetted by histamine (see Figure 1D in Refer-
ence 4).
LPA had no significant effect on the cellular cAMP
concentration at 2, 10, and 30 minutes after stimulation by
LPA, whereas the adenylate cyclase activator forskolin in-
creased cAMP in these cells (Figure III-C). This finding
excludes the possibility that the LPA-increased endothelial
permeability was caused by a reduction of intracellular cAMP
levels.
RhoA Is Involved in LPA-Induced Cytoskeletal
Reorganization and Hyperpermeability
To verify that the effects of LPA on EC barrier functions were
mediated by RhoA, ECs were pretreated with an inhibitor of
RhoA, the C3 transferase from C botulinum, and subse-
quently stained for F-actin and vinculin, a component of focal
adhesion complexes. In confluent ECs, focal contact sites
were hardly detectable (Figure IV-A). Vinculin appeared as a
thin, peripheral band and a diffuse, cytoplasmic staining.
Preincubation of the cells with the RhoA inhibitor C3
transferase (5 mg/mL for 24 hours) had no effect on vinculin
localization (Figures IV-A and IV-D), but the cortical F-actin
network disappeared (Figures IV-B and IV-E). The F-actin
that remained appeared as a thin, peripheral band that
colocalized with vinculin (Figures IV-C and IV-F). The
LPA-induced cytoskeletal changes (Figures IV-G through
Figure II. MLC phosphorylation is stimulated transiently by LPA.
A, Autoradiograph of MLCs immunoprecipitated from cells
under basal conditions (0 minutes) and 2, 5, 10, and 30 minutes
after stimulation with 13 mmol/L LPA. Cells were labeled with
32P and 35S as described previously.4 Top, Exposure in which a
filter was present to block the 35S signal. Bottom, Exposure
without a filter. B, Quantification of MLC phosphorylation. LPA
() significantly increased MLC phosphorylation at 2 and 5 min-
utes. *P,0.05, LPA-stimulated vs nonstimulated cells. Values
are mean6SD of 2 different cultures in duplicate. The level of
32P incorporation into MLCs was calculated relative to the
amount of 35S incorporation into MLCs of the same sample. For
comparison, the effect of 1 U/mL thrombin (F) on MLC phos-
phorylation at 10 minutes is shown. #P,0.05, thrombin stimu-
lated vs nonstimulated cells.
Figure III. [Ca21]I and cAMP levels are not involved in LPA-
induced endothelial barrier dysfunction. A, Representative trac-
ing of changes in cell calcium in human umbilical vein ECs
exposed to LPA (13 mmol/L) and thrombin (1 U/mL). Cells were
loaded with fura 2-AM, and [Ca21]I was monitored as described
in Methods. Similar results were obtained in 4 different cultures.
B, Effect of preincubation with BAPTA on basal (cross-hatched
bars) and LPA-stimulated (hatched bars) HRP passage after 1
hour. Endothelial monolayers were preincubated for 1 hour with
3 mmol/L BAPTA. HRP passage is expressed as a percentage
of basal HRP passage after 1 hour. Values are mean6SEM of 2
different cultures in triplicate. C, Effect of LPA (13 mmol/L) on
cAMP content. Human umbilical vein ECs were preincubated for
1 hour in medium 199 with 1% HSA and stimulated for the
times indicated with LPA (13 mmol/L) or vehicle. Fifteen minutes
before stimulation, cells were preincubated with isobutyl methyl-
xanthine (1 mmol/L). Forskolin (Forsk, 10 mmol/L) was used as a
positive control for cAMP elevation. Data are mean6SEM of 3
different cultures in duplicate.
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IV-I) were completely dependent on the activation of RhoA,
since preincubation of the cells with C3 transferase prevented
the formation of focal adhesion complexes and an increase in
F-actin filaments (Figures IV-J through IV-L). The cells
remained flat.
Preincubation with C3 transferase also completely pre-
vented the LPA-enhanced HRP passage (Figure V-A). Thus,
LPA induced a dramatic change in the endothelial F-actin
cytoskeleton in a RhoA-dependent manner, which was ac-
companied by a RhoA-dependent increase in endothelial
permeability.
To investigate whether ongoing MLC kinase activity was
also required for LPA-enhanced endothelial permeability,
ECs were pretreated with the selective MLC kinase KT5926.
KT5926 reduced basal permeability and completely pre-
vented the LPA-enhanced HRP passage (Figure V-B).
Activation of Rho Kinase Is Essential for
LPA-Enhanced Permeability
Recent data pointed to a role for Rho kinase, 1 of the targets
of RhoA, in the formation of stress fibers and cell contrac-
tion.19,21 The Rho kinase inhibitor Y-27632 was used to study
the role of Rho kinase in the LPA-induced endothelial barrier
dysfunction. We first stained ECs for F-actin to verify that
Rho kinase is involved in the LPA-induced EC cytoskeletal
reorganization. Analogous to C3 transferase, Y-27632 com-
pletely prevented the LPA-induced F-actin polymerization
(Figure VI-A).
Subsequently, endothelial monolayers were preincubated
for 1 hour with 10 mmol/L Y-27632. Preincubation with
Y-27632 had no significant effect on basal permeability
(Figure VI-B) but completely prevented the LPA-induced
increase in HRP passage. Thus, activation of Rho kinase by
LPA is necessary for the proper formation of stress fibers and
enhanced barrier dysfunction.
Discussion
In the present study, we have shown that activation of Rho by
LPA is required to induce a prolonged increase in endothelial
permeability in the absence of a rise in [Ca21]i. Furthermore,
it was shown that LPA induces a transient increase in MLC
phosphorylation and that the effect of LPA on barrier func-
tion was mediated by Rho kinase.
We have previously reported that, in addition to its role in
the elevation in the number of Ca21 ions, activation of Rho is
necessary for the thrombin-induced MLC phosphorylation
and enhanced endothelial permeability.4 A model was postu-
lated in which the prolonged effect of thrombin on endothe-
lial barrier function was mediated by a Rho-dependent
sensitization of a transient, Ca21/calmodulin-dependent MLC
phosphorylation, comparable to the calcium sensitization that
is known from smooth muscle cells.29 In the present study,
the specific Rho activator LPA was used to study Rho-
mediated mechanisms of endothelial permeability. In contrast
to thrombin-enhanced endothelial permeability,4 which is
only partially dependent on the activation of RhoA, LPA-
enhanced permeability was completely blocked by the inhi-
bition of either Rho or Rho kinase.
Rather high concentrations of LPA were necessary to
induce endothelial hyperpermeability. This may have resulted
from partial desensitization of the LPA receptors. LPA is
known to be present in serum in concentrations of up to
Figure IV. LPA-induced cytoskeletal reorganization is com-
pletely RhoA dependent. Immunocytochemical staining of vincu-
lin (A, D, G, J), F-actin (B, E, H, K), or both (C, F, I, L). Human
umbilical vein ECs were preincubated for 24 hours with 5 mg/mL
C3 transferase and stimulated with 13 mmol/L LPA. Actin and
vinculin were visualized as described in Methods. A–C, Basal
condition; D–F, J–L, cells were preincubated with C3 trans-
ferase; G–L, cells were stimulated for 30 minutes with LPA. Sim-
ilar results were observed in 3 different cultures.
Figure V. Effect of C3 transferase and KT5926 on basal and
LPA-enhanced permeability. Endothelial monolayers were pre-
treated for 24 hours with 5 mg/mL C3 transferase (A) or for 30
minutes with 10 mmol/L KT5926 (B). HRP passage was deter-
mined 1 hour after sham treatment (filled bars) or exposure to
13 mmol/L LPA (hatched bars). Values are mean6SEM of 6 filter
cultures of 2 different donors. *P,0.05, cells that were pre-
treated with C3 transferase vs nonpretreated cells. #P,0.05,
cells that were pretreated with KT5926 vs nonpretreated cells.
Figure VI. Effect of inhibition of Rho kinase on LPA-induced
endothelial permeability. A, Immunocytochemical staining of
F-actin. ECs were pretreated for 1 hour with 10 mmol/L Y-27632
(c, d) and stimulated for 30 minutes with 13 mmol/L LPA (b, d).
Similar results were observed in 3 different cultures. B, Effect of
preincubation with Y-27632 on basal (cross-hatched bars) and
LPA-stimulated (hatched bars) HRP passage after 1 hour. Endo-
thelial monolayers were preincubated for 1 hour with 10 mmol/L
Y-27632. HRP passage is expressed as a percentage of basal
HRP passage after 1 hour. Values are mean6SEM of 2 different
cultures in triplicate. *P,0.05, cells that were pretreated vs non-
pretreated cells.
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2 mmol/L. Our cells were cultured in 20% serum and
therefore exposed to a concentration of LPA that is in the
range of reported receptor affinities.9 Prolonged exposure to
LPA results in downregulation of LPA receptors.30 Thus, it is
likely that the effect of LPA on endothelial barrier function is
underestimated.
Several lines of evidence indicated that the LPA-induced
endothelial permeability is Ca21 independent. First, after
exposure to LPA, no detectable rise in [Ca21]i could be
observed in the EC monolayers that responded to thrombin
with respect to Ca21 mobilization. Second, chelation of Ca21i
ions had no effect on the LPA-induced HRP passage. Thus,
besides acting as a sensitizer for Ca21-induced changes in
thrombin-enhanced endothelial permeability,4 activation of
RhoA induces endothelial permeability, even without a
change in [Ca21]i. This result agrees with the finding in a
previous report in which Ca21-independent but Rho-
dependent hyperpermeability induced by Pasteurella multo-
cida toxin was suggested.31 It should be noted that in ECs,
MLC kinase is active at a low degree,32 which explains why
inhibition of MLC kinase by KT5926 reduced basal HRP
passage. This basal MLC kinase activity was also required for
the LPA-enhanced HRP passage, in agreement with previous
reports that indicated that ongoing MLC kinase activity is
involved in the cytoskeletal effects of LPA.31,33,34 In fibro-
blasts, it has been shown that LPA lowers cAMP levels,
probably by coupling GI proteins to an LPA receptor,35 and
cAMP is known to improve endothelial barrier function.25–27
However, LPA did not significantly lower cAMP levels in
ECs, excluding the possibility of a reduction in cAMP levels
as the mechanism of LPA action.
Our finding that LPA induces endothelial permeability for
macromolecules agrees with a previous report that showed an
increase in tight junction permeability of pig brain capillary
ECs by LPA.36 In a recent report by those investigators, it was
shown that LPA caused a serine/threonine dephosphorylation
of the cadherin-associated adherens junctional proteins
catenins p120 and p100 in a protein kinase C–independent
way.37 From these data, they suggested that LPA can actively
regulate the opening of adherens junctions. Other studies do
not favor a role for Rho proteins in the regulation of adherens
junctions in ECs. Braga et al38 showed that ECs are excep-
tional in this sense. They demonstrated that in contrast to
other cell types, Rho activity is not necessary for cadherin-
based, endothelial cell-cell interaction and that VE-cadherin
localization was insensitive to the inhibition of either Rho or
Rac. This scenario fits with our finding that inhibition of
RhoA and Rho kinase did not disrupt the cortical F-actin
band, although it reduced the F-actin of ECs, and that
inhibition of Rho kinase did not decrease basal endothelial
barrier function. Furthermore, Essler et al5 showed that
inhibition of Rho by C3 transferase did not prevent the
thrombin-induced dissociation of catenins from the cytoskel-
eton. Wojciak-Stothard et al39 showed that the Cdc42-, Rac-,
and Rho-dependent TNF-a–induced stress-fiber formation
was also accompanied, at least partly, by a Cdc42-, Rac-, and
Rho-independent dispersion of VE-cadherin from intercellu-
lar junctions. Thus, at the moment, there is no firm support
for a role for Rho proteins in the direct regulation of adherens
junction organization in ECs. However, an indirect effect on
proteins associated with adherens proteins cannot yet be
excluded. This possibility still exists, because Rho kinase also
acts on other proteins, such as adducin and members of the
ezrin/radixin/moesin family.40 Recent data from Fukata et al40
indicate that phosphorylation of adducin by Rho kinase
activates the association of an F-actin–spectrin meshwork
with the plasma membrane. Such a mechanism may affect the
organization of cytoskeleton anchoring with the plasma
membrane and junction complexes.
In bovine aortic endothelial monolayers, Alexander et al41
observed an improvement of barrier function after stimulation
with LPA. These apparently contrasting results are not caused
by tissue-specific differences, because in our experience with
human aortic endothelial monolayers, LPA decreased barrier
function comparably to human umbilical vein EC monolayers
(van Nieuw Amerongen et al, unpublished observations,
1999) but may reflect species differences.
The LPA-induced endothelial barrier dysfunction requires
Rho kinase activity, as was shown by inhibition of this kinase
by Y-27632. With respect to endothelial permeability, partic-
ular attention has been paid to its effect on MLC phosphor-
ylation. Rho kinase can increase MLC phosphorylation by
inhibiting the myosin phosphatase17,18 or by its capacity to
phosphorylate the MLC itself.19 The former appears the most
likely mechanism of Rho kinase–induced MLC phosphory-
lation in ECs, since it was shown that myosin phosphatase is
inhibited by thrombin in ECs.32,42,43
A surprising finding of our study was that in contrast to the
prolonged effect of LPA on endothelial barrier function, MLC
phosphorylation was elevated only transiently by LPA. This
suggests that a transient MLC phosphorylation is sufficient to
induce a prolonged EC contraction comparable to the latch-
bridge state in smooth muscle cells, wherein maintenance of
contraction occurs despite MLC dephosphorylation.44
A transient MLC phosphorylation does not necessarily lead
to prolonged barrier dysfunction. Histamine was shown
previously4 to induce a very similar MLC phosphorylation,
but it reduced barrier function in a transient and Rho-
independent way. This finding suggests that either histamine
activates a fast, unknown recovery process that is not acti-
vated by LPA or that LPA, in addition to MLC phosphory-
lation, does something more that results in a prolonged barrier
dysfunction. It is plausible to suggest that the Rho kinase–
induced focal adhesion formation20 or other actions of Rho
kinase on the cytoskeleton45 contribute to this prolongation.
However, the contribution of additional factors activated by
LPA cannot be excluded. Phosphatidylinositol 4,5-
biphosphate (PIP2) may be involved, as intracellular levels of
PIP2 can be increased after activation of Rho46 and PIP2 is
known to interfere with the actin cytoskeleton.47 Furthermore,
the activation of protein tyrosine kinases by LPA may also
contribute to prolonged changes in the regulation of the
cytoskeleton or cell-cell junctions.48–52
The increase in MLC phosphorylation precedes the appear-
ance of stress fibers and focal adhesions. This sequence fits
nicely with the model of Chrzanowska-Wodnicka and Burr-
idge,33 who showed that the Rho-induced MLC phosphory-
lation and tension development precede the assembly of
stress fibers in fibroblast cells. The role of stress fibers in
permeability is not precisely known and requires further
investigation. They probably reflect actin–nonmuscle myosin
interactions but do not necessarily per se contribute to a state
van Nieuw Amerongen et al Rho Kinase in LPA-Induced Permeability 5
 at Vrije on July 29, 2011http://atvb.ahajournals.org/Downloaded from 
of prolonged contraction of the ECs. Stress fibers obviously
have contractile properties,53 but on the other hand, they also
stabilize ECs in regions of high shear. 34,54
Our data point to an important role of Rho and Rho kinase
in the regulation of endothelial permeability. Future studies
will need to demonstrate if and when these factors are
involved in altered endothelial barrier function in vivo. In
large-vessel ECs, in particular in areas with altered shear
forces, stress fibers are found and Rho-mediated processes
are likely to be involved. No information is presently avail-
able on microvascular ECs in vivo. However, it should be
noted that Rho kinase plays a role in cell migration and that
prolonged permeability might be a reflection of the altered
behavior of ECs during cell migration and angiogenesis,
which occur in wound healing and pathological conditions.
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